Silverarc Capital Management LLC Purchases 25,955 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Silverarc Capital Management LLC lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 64.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,955 shares of the company's stock after acquiring an additional 25,955 shares during the quarter. Silverarc Capital Management LLC owned approximately 0.17% of Tarsus Pharmaceuticals worth $3,652,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of TARS. JPMorgan Chase & Co. lifted its position in shares of Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock worth $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Jennison Associates LLC lifted its holdings in Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after buying an additional 321,552 shares in the last quarter. Invesco Ltd. boosted its position in Tarsus Pharmaceuticals by 36.7% in the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock valued at $51,611,000 after buying an additional 250,018 shares during the last quarter. Atika Capital Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $9,812,000. Finally, Lord Abbett & CO. LLC raised its position in shares of Tarsus Pharmaceuticals by 28.4% during the third quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company's stock worth $19,565,000 after acquiring an additional 131,636 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TARS. Guggenheim reiterated a "buy" rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $63.67.

Tarsus Pharmaceuticals Trading Up 0.1 %

Shares of Tarsus Pharmaceuticals stock traded up $0.03 during trading hours on Friday, hitting $50.00. The company's stock had a trading volume of 754,503 shares, compared to its average volume of 688,742. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a 50 day moving average of $47.60 and a 200 day moving average of $48.25. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a market capitalization of $1.92 billion, a PE ratio of -13.12 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to analysts' expectations of $58.80 million. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 2,315 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares of the company's stock, valued at $2,349,263.79. This trade represents a 4.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bobak R. Azamian sold 7,131 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the completion of the sale, the chief executive officer now owns 70,720 shares in the company, valued at $3,273,628.80. This trade represents a 9.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 in the last 90 days. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.